Invasive Pneumococcal Disease Epidemiology and Serotype Replacement After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Ontario, Canada, 2007-2022.

Ramandip GrewalKelty HillierShelley L DeeksAllison H YeungSarah E WilsonShinthuja WijayasriTara M HarrisSarah E Wilson

Published in: Open forum infectious diseases (2024)

IPD incidence and hospitalizations due to PCV13 serotypes decreased after PCV13 introduction but increased for other serotypes. Continued surveillance is required to evaluate changes to pneumococcal vaccination programs and ongoing changes to the distribution of IPD-causing serotypes.

Keyphrases

public health
risk factors
cancer therapy
escherichia coli
klebsiella pneumoniae
multidrug resistant